Medtronic's Mixed Q4 Earnings Report
Medtronic's top line saw growth in Q4 and full-year, but that growth disappeared in the bottom-line figures. Medtronic management was positive in its outlook for fiscal 25 with projected organic re...
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase
Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cyc...
Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade
Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
Medtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for ...
HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17, 2024...
Late-breaking data show reliable performance of small-diameter defibrillation lead, the Medtronic OmniaSecure™
Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm DUBLIN and BOSTON , May 17, 2024 /PRNewswi...
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
In the closing of the recent trading day, Medtronic (MDT) stood at $83.52, denoting a +0.82% change from the preceding trading day.
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
Arecor shares higher after Medtronic deal; broker remains upbeat
Shares in Arecor Therapeutics PLC (AIM:AREC) rose in the wake of news it is teaming with US med-tech giant Medtronic to develop a new, high-concentration, thermostable insulin designed specifically...
Medtronic to announce financial results for its fourth quarter and full fiscal year 2024
DUBLIN , May 9, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal...
Arecor Therapeutics agrees insulin tie-up with US med-tech giant Medtronic
Arecor Therapeutics PLC (AIM:AREC) said it is teaming with US med-tech giant Medtronic to develop a new, high-concentration, thermostable insulin designed specifically for use in the latter's next-...
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
The latest trading day saw Medtronic (MDT) settling at $81.76, representing a +0.09% change from its previous close.
Medtronic (MDT) Rises Higher Than Market: Key Facts
Medtronic (MDT) closed at $80.86 in the latest trading session, marking a +1.4% move from the prior day.
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Related Companies